Mark T Iwicki Kala Pharmaceuticals, Inc. (KALA) insider trading activity

Mark T Iwicki is of Kala Pharmaceuticals, Inc.. Currently has a direct ownership of 103,540 shares of KALA, which is worth approximately $73,513. The most recent transaction as insider was on Oct 23, 2025, when has been sold 154,894 shares (Common Stock) at a price of $0.81 per share, resulting in proceeds of $125,464. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 104K

59.94% 3M change

60.74% 12M change

Total Value Held $73,513

Mark T Iwicki Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 23 2025	SELL Open market or private sale	$125,464 $0.81 p/Share	154,894 Reduced 59.94%	103,540 Common Stock
Jun 24 2025	SELL Open market or private sale	$53,040 $4.01 p/Share	13,227 Reduced 4.87%	258,433 Common Stock
Jun 15 2025	BUY Grant, award, or other acquisition	-	2,450 Added 0.89%	271,660 Common Stock
Jun 03 2025	BUY Open market or private sale	$40,638 $3.74 p/Share	10,866 Added 3.88%	269,210 Common Stock
Jan 06 2025	SELL Open market or private sale	$44,093 $7.63 p/Share	5,779 Reduced 2.02%	280,076 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	22,100 Added 7.18%	285,855 Common Stock
Jun 26 2024	SELL Open market or private sale	$72,048 $4.75 p/Share	15,168 Reduced 5.44%	263,755 Common Stock
May 31 2024	SELL Open market or private sale	$45,017 $6.09 p/Share	7,392 Reduced 2.58%	278,923 Common Stock
Jan 04 2024	SELL Open market or private sale	$30,547 $6.73 p/Share	4,539 Reduced 1.56%	286,315 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	14,300 Added 4.69%	290,854 Common Stock
Jun 22 2023	BUY Grant, award, or other acquisition	-	158,873 Added 36.49%	276,554 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	-	71,715 Added 37.87%	117,681 Common Stock
Jan 04 2023	SELL Open market or private sale	$5,650 $28.54 p/Share	198 Reduced 0.43%	45,966 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	41,700 Added 47.46%	46,164 Common Stock
Oct 26 2022	SELL Open market or private sale	$3,658 $6.52 p/Share	561 Reduced 11.16%	4,464 Common Stock
Jun 27 2022	SELL Open market or private sale	$2,951 $0.37 p/Share	7,975 Reduced 3.08%	251,183 Common Stock
Jan 04 2022	SELL Open market or private sale	$12,373 $1.3 p/Share	9,518 Reduced 3.54%	259,158 Common Stock
Oct 26 2021	SELL Open market or private sale	$49,676 $1.8 p/Share	27,598 Reduced 9.32%	268,676 Common Stock
Jun 28 2021	SELL Open market or private sale	$43,771 $5.77 p/Share	7,586 Reduced 2.5%	296,274 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	76,000 Added 20.01%	303,860 Common Stock
Oct 26 2020	BUY Grant, award, or other acquisition	-	178,300 Added 43.9%	227,860 Common Stock

Also insider at

PULM

Pulmatrix, Inc. Healthcare

Director

MRUS

Merus N.V. Healthcare

AKRO

Akero Therapeutics, Inc. Healthcare

AVTE

Aerovate Therapeutics, Inc. Healthcare

IKT

Inhibikase Therapeutics, Inc. Healthcare

Chief Executive Officer

THRD

Third Harmonic Bio, Inc. Healthcare

FIXX

Homology Medicines, Inc. Healthcare

MTI

Mark T Iwicki

Utretcht, P7

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALA shares.

Notify only if

Value

Insider Trading

Get notified when an Kala Pharmaceuticals, Inc. insider buys or sells KALA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kala Pharmaceuticals, Inc.

Track Activities on KALA

Account